BioMarin Pharmaceutical (BMRN) total liabilities
BioMarin Pharmaceutical (BMRN) had total liabilities of $1.51B at the end of fiscal 2025 (December 31, 2025). That is 13.2% higher than the $1.33B of fiscal 2024. Figures as of 18 Nov 2026, 23:55 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $1.51B
- Change on fiscal 2024
- +13.2%
- Growth, 5 years
- −2.9% a year
- Growth, 10 years
- +1.3% a year
- Highest on record
- $1.89Bfiscal 2023
- Lowest on record
- $532.66Mfiscal 2011
- Fiscal years on record
- 172009–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
BioMarin Pharmaceutical total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities shrank at a compound 2.9% a year; over ten years the rate was 1.3% a year. Across the 17 fiscal years on record (2009–2025), the highest was $1.89B in fiscal 2023 and the lowest $532.66M in fiscal 2011.
Total liabilities by fiscal year
BioMarin Pharmaceutical total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $1.51B | 13.2% up | |
| 2024 | $1.33B | 29.6% down | |
| 2023 | $1.89B | 6.7% up | |
| 2022 | $1.77B | 1.9% up | |
| 2021 | $1.74B | 0.2% down | |
| 2020 | $1.74B | 11.1% up | |
| 2019 | $1.57B | 7.4% up | |
| 2018 | $1.46B | 20.0% down | |
| 2017 | $1.82B | 45.1% up | |
| 2016 | $1.26B | 5.4% down | |
| 2015 | $1.33B | 40.2% up | |
| 2014 | $947.49M | 4.9% up | |
| 2013 | $903.02M | 63.4% up | |
| 2012 | $552.58M | 3.7% up | |
| 2011 | $532.66M | 2.3% down | |
| 2010 | $545.37M | 8.3% down | |
| 2009 | $594.98M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Universal Health Services UHS | $8.12B | 2025 |
| Repligen RGEN | $843.57M | 2025 |
| Bio-Techne TECH | $478.51M | 2026 |
| BioMarin Pharmaceutical BMRN | $1.51B | 2025 |
| Avantor AVTR | $6.23B | 2025 |
| Ensign Group ENSG | $3.23B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
BioMarin Pharmaceutical, figure by figure
- BioMarin Pharmaceutical market cap
- BioMarin Pharmaceutical revenue
- BioMarin Pharmaceutical earnings
- BioMarin Pharmaceutical earnings per share (EPS)
- BioMarin Pharmaceutical P/E ratio
- BioMarin Pharmaceutical P/S ratio
- BioMarin Pharmaceutical P/B ratio
- BioMarin Pharmaceutical free cash flow
- BioMarin Pharmaceutical operating margin
- BioMarin Pharmaceutical dividend
- BioMarin Pharmaceutical shares outstanding
- BioMarin Pharmaceutical total debt
- BioMarin Pharmaceutical cash on hand
- BioMarin Pharmaceutical total assets
- BioMarin Pharmaceutical net assets (shareholders' equity)
- BioMarin Pharmaceutical return on equity (ROE)
- BioMarin Pharmaceutical return on invested capital (ROIC)
BioMarin Pharmaceutical (BMRN) overview: price, valuation and scorecardAll health care companies by market value
BioMarin Pharmaceutical total liabilities: questions and answers
How large are BioMarin Pharmaceutical's total liabilities?
BioMarin Pharmaceutical (BMRN) had total liabilities of $1.51B at the end of fiscal 2025 (December 31, 2025). That is 13.2% higher than the $1.33B of fiscal 2024.
What is the growth rate of BioMarin Pharmaceutical's total liabilities?
Over the five fiscal years to 2025 total liabilities shrank at a compound 2.9% a year; over ten years the rate was 1.3% a year.
What are the highest and lowest total liabilities figures on record for BioMarin Pharmaceutical?
Across the 17 fiscal years on record (2009–2025), the highest was $1.89B in fiscal 2023 and the lowest $532.66M in fiscal 2011.
How is BioMarin Pharmaceutical's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For BioMarin Pharmaceutical it is on record here for 17 fiscal years, 2009 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “BioMarin Pharmaceutical (BMRN) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/BMRN/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.